More control
A task completed with less effort. Movement that supports participation.
A treatment should be measured by more than a laboratory signal. The goal is meaningful change in the lives of people affected by Kernicterus.
Kernicterus can affect movement, hearing, eye movements, and other functions. People’s experiences and abilities vary. Difficulties with movement or speech should not be assumed to reflect understanding.
In our envisioned development model, individuals and families help shape research priorities, accessible study design, and the interpretation of meaningful outcomes.
That includes the burden of participation: travel, communication, fatigue, and the demands of everyday life.
A task completed with less effort. Movement that supports participation.
Communication and hearing-related outcomes that matter to the person.
Greater choice, comfort, independence, and quality of life.
Illustrative goals, not reported treatment outcomes or testimonials.
No. This is a hypothetical future-state website. No Kitheras products, clinical trials, or treatment services are available.
There is currently no proven cure. Individualized care can address symptoms and support daily life. Discuss medical decisions with your healthcare team.
No. Phototherapy is used to lower bilirubin and help prevent injury in newborns. It does not reverse established Kernicterus.
No. The pipeline is illustrative and there is no study enrollment, patient registry, or expanded-access program. This concept does not collect health information.
PIC-K provides prevention, awareness, and family resources. Visit archived CDC family information for background. These are separate resources and do not imply affiliation.
Lived experience belongs at the center of therapeutic development.